• 3D Tumor Spheroids for Glioblastoma Stemness

  2026-08-23

  Chen et al. present a streamlined 96-well 3D-tumor spheroid assay for functional assessment of stem-like phenotypes in glioblastoma cell lines. By replacing a slower two-round sphere-forming workflow with a compact seeding, centrifugation, and imaging procedure, the method supports reproducible mechanistic studies and higher-throughput screening while still requiring orthogonal validation.

• Neomycin sulfate for RNA, DNA, and Channel Assays

  2026-08-22

  Neomycin sulfate is an aminoglycoside antibiotic repurposed as a mechanistic probe for structured RNA, DNA triplexes, HIV-1 TAR recognition, and ryanodine receptor conductance. This workflow-focused guide explains how to choose concentrations, separate binding from catalysis, and control matrix effects without confusing exploratory antibiotic exposure with disease-treatment evidence.

• Xenopus laevis Pluripotency Network Rewiring

  2026-08-21

  The reference study shows that hybridization rewired early pluripotency regulation in allotetraploid Xenopus laevis through asymmetric activation of homeologous genes and divergent enhancer architectures. Despite this regulatory divergence, combined L- and S-subgenome expression preserves the dosage of core embryonic transcriptional programs, revealing how selection can stabilize development after genome duplication.

• From Kinases to Condensates: A Translational Playbook

  2026-08-21

  A mechanistic and strategic framework for using the CK2 and ERK8 inhibitor as a controlled perturbation tool in kinase signaling, protein interaction, and phase-separation research—without overstating an unproven antiviral mechanism.

• MG-132 (Z-LLL-al) for Proteasome Assays

  2026-08-20

  MG-132 (Z-LLL-al) provides a cell-permeable way to perturb proteasome-dependent protein turnover while tracking apoptosis, cell cycle arrest, oxidative stress, and mitochondrial quality control. Its most useful application is comparative mechanism testing: pair proteasome inhibition with ubiquitination, LC3, ROS, viability, and mitochondrial readouts rather than treating it as a pathway-specific mitophagy reagent.

• MCL1 Resistance Biology Meets L1023 Screening

  2026-08-20

  MCL1-mediated apoptosis resistance is a compelling test case for translating mechanistic oncology findings into pathway-aware screening. This article shows how the DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023) can support structured comparison of apoptosis, kinase, proteostasis, and mTOR-linked dependencies without mistaking a phenotypic hit for a validated target mechanism.

• Berbamine Hydrochloride as a Ferroptosis Probe

  2026-08-19

  Explore how Berbamine hydrochloride can be used as an NF-κB activity inhibitor and experimental perturbation tool in cancer research. This article translates the METTL16-SENP3-LTF ferroptosis findings into practical assay strategies without overclaiming direct pathway targeting.

• Triptolide (PG490): Phase-Aware Assay Design

  2026-08-19

  Triptolide (PG490) is a potent transcriptional inhibitor with applications in cancer research, immunology, and inflammatory disease models. This guide introduces a phase-aware strategy that connects its RNAPII-centered activity with cell-cycle transcription condensate biology to improve assay timing, controls, and interpretation.

• Microfluidic Peptide–RNA Complexes for Lung Delivery

  2026-08-18

  This 2025 study shows that microfluidic mixing can reproducibly prepare LAH4-L1 and PEG12KL4 peptide complexes with siRNA or mRNA for nebulized pulmonary delivery. The complexes generated inhalable aerosols and retained RNA binding and in vitro transfection performance after vibrating-mesh nebulization, supporting further development of peptide-based mRNA delivery system research.

• EPZ5676: A Practical DOT1L Inhibitor Workflow

  2026-08-18

  EPZ5676 combines sub-nanomolar biochemical potency with strong selectivity, making it a useful reference compound for H3K79 methylation inhibition and MLL-rearranged leukemia research. This guide connects biochemical testing, cellular target engagement, chromatin assays, and troubleshooting while clarifying how a rectal organoid study can inform—not replace—DOT1L-specific experiments.

• Aconitase Activity Colorimetric Assay Kit Guide

  2026-08-17

  The Aconitase Activity Colorimetric Assay Kit provides a rapid biochemical readout of citrate-to-isocitrate conversion through color development at 450 nm. K2226 is useful for TCA cycle enzyme assay workflows and oxidative damage measurement, but its signal should not be interpreted as a direct measurement of reactive oxygen species or aconitase abundance.

• α-Amanitin: From RNAP II Probe to Translational Insight

  2026-08-17

  α-Amanitin is more than a potent RNA polymerase II inhibitor: it is a causal perturbation tool for connecting transcriptional control to phenotype. This thought-leadership guide integrates mechanism, assay design, product strategy, and the emerging toxicology relevance of α-amanitin, including insights from CRISPR screening and STT3B biology.

• CCK-8, Endogenous Opioids, and Withdrawal Anxiety

  2026-08-16

  Wen et al. showed that cholecystokinin octapeptide (CCK-8) reduces anxiety-like behavior in morphine-withdrawal rats through CCK1 receptor signaling and endogenous opioid involvement. The pharmacological design separates CCK1-dependent modulation from μ-opioid receptor-dependent effects, offering a mechanistic framework for opioid addiction and withdrawal studies.

• Nonselective β-Blockers and HCT Engraftment

  2026-08-15

  The reference study shows that nonselective β-adrenergic receptor inhibitors can impair hematopoietic regeneration after allogeneic hematopoietic cell transplantation, whereas β1-selective inhibition had little comparable effect. By integrating mouse transplantation models with human clinical cohorts, the work identifies β-blocker selectivity, transplant type, posttransplant chemotherapy, and graft size as important determinants of engraftment risk.

• Protease Inhibition as a Translational Strategy

  2026-08-14

  Proteases are not simply degradative enzymes; they are context-dependent regulators of signaling, cell death, proteostasis, and disease progression. This article examines how broad chemical perturbation can connect protease activity modulation with translational hypotheses, using the PSMD14–CARM1–FERMT1 axis in hepatocellular carcinoma as a mechanistic anchor. It also provides practical guidance for deploying the DiscoveryProbe™ Protease Inhibitor Library in biochemical, cellular, and high-content workflows while distinguishing exploratory evidence from disease-relevant validation.

595 records 10/40 page Previous Next First page 上5页 678910 下5页 Last page